References

akusherstvo

Obstetrics, Gynecology and Reproduction

Акушерство, Гинекология и Репродукция

2313-73472500-3194

IRBIS LLC

10.17749/2313-7347/ob.gyn.rep.2025.678

akusherstvo-2578

Research Article

REVIEW ARTICLES

НАУЧНЫЕ ОБЗОРЫ

Menopause, postmenopausal osteoporosis, and dental implantation: the role of menopausal hormone therapy

Менопауза, постменопаузальный остеопороз и дентальная имплантация: роль менопаузальной гормональной терапии

https://orcid.org/0009-0006-0315-922X

Медведева

Е. В.

Medvedeva

E. V.

Медведева Екатерина Владимировна

101025 Санкт-Петербург, ул. Марата, д. 6

Ekaterina V. Medvedeva

33 bldg. 1, Gakkelevskaya Str., Saint Petersburg 197227

katya-110@mail.ru

https://orcid.org/0000-0003-4696-9290

Иванов

Н. В.

Ivanov

N. V.

Иванов Никита Владимирович, к.м.н.

Scopus Author ID: 57221190481.

WoS ResearcherID: JRZ-0207-2023.

191015 Санкт-Петербург, Кирочная ул., д 41

Республика Узбекистан, 170127 Андижан, ул. Атабекова, д. 1

Россия, 197227 Санкт-Петербург, ул. Гаккелевская, д. 33, корп. 1

Nikita V. Ivanov, MD, PhD

Scopus Author ID: 57221190481

WoS ResearcherID: JRZ-0207-2023

41 Kirochnaya Str., Saint Petersburg 191015

1 Atabekov Str., Andijan 170127, Republic of Uzbekistan

33 bldg. 1, Gakkelevskaya Str., Saint Petersburg 197227

baltic.forum@gmail.com

https://orcid.org/0009-0008-5688-7700

Веснина

А. Ф.

Vesnina

A. F.

Веснина Анна Федоровна, к.м.н.

117036 Москва, ул. Дмитрия Ульянова, д. 11

Anna F. Vesnina, PhD

11 Dmitry Ulyanov Str., Moscow 117036

https://orcid.org/0000-0002-8215-6898

Хромова

Е. А.

Khromova

E. A.

Хромова Елена Алексеевна, к.м.н.

191015 Санкт-Петербург, Кирочная ул., д. 41

Elena A. Khromova, PhD

41 Kirochnaya Str., Saint Petersburg 191015

https://orcid.org/0000-0001-5641-9239

Юсупова

Ш. К.

Yusupova

Sh. K.

Юсупова Шахноза Кадиржановна, д.м.н.

Scopus Author ID: 59418272100

WoS ResearcherID: AEX-6726-2022

170127 Андижан, ул. Атабекова, д. 1

Shakhnоza K. Yusupova, MD, Dr Sci Med.

Scopus Author ID: 59418272100

WoS ResearcherID: AEX-6726-2022

1 Atabekov Str., Andijan 170127

АО группа компаний «Медси»РоссияMedsi Group of Companies JSCRussian Federation

АО группа компаний «Медси»; ФГБОУ ВО «Северо-Западный государственный медицинский университет имени И.И. Мечникова» Министерства здравоохранения Российской Федерации; Андижанский государственный медицинский институтРоссияMedsi Group of Companies JSC; Mechnikov North-Western State Medical University, Ministry of Health of the Russian Federation; Andijan State Medical InstituteRussian Federation

ФГБУ «Национальный медицинский исследовательский центр эндокринологии имени академика И.И. Дедова» Министерства здравоохранения Российской ФедерацииРоссияDedov National Medical Research Center for Endocrinology, Ministry of Health of the Russian FederationRussian Federation

ФГБОУ ВО «Северо-Западный государственный медицинский университет имени И.И. Мечникова» Министерства здравоохранения Российской ФедерацииРоссияMechnikov North-Western State Medical University, Ministry of Health of the Russian FederationRussian Federation

Андижанский государственный медицинский институтУзбекистанAndijan State Medical InstituteUzbekistan

2025

19012026

196

966–975

2026

Медведева Е.В., Иванов Н.В., Веснина А.Ф., Хромова Е.А., Юсупова Ш.К.

Medvedeva E.V., Ivanov N.V., Vesnina A.F., Khromova E.A., Yusupova S.K.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.gynecology.su/jour/article/view/2578

Here, we summarize current evidence on the impact of postmenopausal osteoporosis, menopause-related hormonal changes, and hormone therapy on dental implant outcomes. Epidemiology and pathogenesis of bone alterations are reviewed, with particular emphasis on the role of estrogen, progesterone, calcitonin, growth hormone, and insulin-like growth factor-1 (IGF-1) deficiency. Special attention is paid to the effects of menopausal hormone therapy and bioidentical forms of estradiol and progesterone on osteoporosis course and the effectiveness of dental implantation. The analysis highlights the risks of implant loss and the opportunities of interdisciplinary approach in dentistry and endocrinology to optimize implant osseointegration in postmenopausal women.

В статье обобщены современные данные о влиянии постменопаузального остеопороза, гормональных изменений в менопаузе и гормональной терапии на исходы дентальной имплантации. Рассмотрены эпидемиология, патогенез костных изменений, роль дефицита эстрогенов, прогестерона, кальцитонина, гормона роста и инсулиноподобного фактора роста. Особое внимание уделено влиянию менопаузальной гормональной терапии, биоидентичных форм эстрадиола и прогестерона на течение остеопороза и эффективность дентальной имплантации. Представлен анализ рисков потери дентальных имплантатов и возможности междисциплинарного подхода в стоматологии и эндокринологии для оптимизации остеоинтеграции имплантатов у пациенток в постменопаузе.

постменопаузальный остеопороздентальная имплантацияменопаузальная гормональная терапиябиоидентичные половые гормоныантирезорбтивная терапияостеоанаболическая терапияальвеолярная кость

postmenopausal osteoporosisdental implantationmenopausal hormone therapybioidentical sex hormonesantiresorptive therapyosteoanabolic therapyalveolar bone

References1

Baber R., Panay N., Fenton A. IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–50. https://doi.org/10.3109/13697137.2015.1129166.

Симонова Г.И., Лила А.М., Торопцова Н.В., Беневоленская Л.И. Остеопороз: современное состояние проблемы. Научно-практическая ревматология. 2019;57(6):653–60. https://doi.org/10.17116/terarkh201789590-97.

Simonova G.I., Lila A.M., Toroptsova N.V., Benevolenskaya L.I. Osteoporosis: current state of the problem. [Osteoporoz: sovremennoe sostoyanie problemy]. Nauchno-prakticheskaya revmatologiya. 2019;57(6):653–60. (In Russ.). https://doi.org/10.17116/terarkh201789590-97.

Eastell R., Rosen C.J., Black D.M. et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update. J Clin Endocrinol Metab. 2019;104(5):1595–622. https://doi.org/10.1210/jc.2019-00221.

Reginster J.-Y., Burlet N. Osteoporosis: a still increasing prevalence. Bone. 2006;38(2):4–9. https://doi.org/10.1016/j.bone.2005.11.024.

Lane N.E. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol. 2006;194(2 Suppl):S3–11. https://doi.org/10.1016/j.ajog.2005.08.047.

Temmerman A., Rasmusson L., Kubler A., Thor A. A prospective, randomized, controlled clinical trial on the long-term effect of osteoporosis on implant treatment. Clin Oral Implants Res. 2017;28(2):171–80. https://doi.org/10.1177/0022034518798804.

Alsaadi G., Quirynen M., Komarek A., van Steenberghe D. Impact of local and systemic factors on the incidence of oral implant failures, up to abutment connection. J Clin Periodontol. 2007;34(7):610–7. https://doi.org/10.1111/j.1600-051x.2007.01077.x.

Hernlund E., Svedbom A., Ivergard M. et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. Arch Osteoporos. 2013;8:136. https://doi.org/10.1007/s11657-013-0136-1.

International Osteoporosis Foundation. Facts and statistics. Режим доступа: https://www.osteoporosis.foundation/facts-statistics. [Дата обращения: 28.08.2025].

Торопцова Н.В., Беневоленская Л.И., Лила А.М. Распространенность остеопороза и переломов в Российской Федерации: данные многоцентрового эпидемиологического исследования. Научно-практическая ревматология. 2018;56(1):15–23.

Toroptsova N.V., Benevolenskaya L.I., Lila A.M. Prevalence of osteoporosis and fractures in the Russian Federation: data from a multicenter epidemiological study. [Rasprostranennost’ osteoporoza i perelomov v Rossiyskoy Federatsii: dannye mnogotsentrovogo epidemiologicheskogo issledovaniya]. Nauchno-prakticheskaya revmatologiya. 2018;56(1):15–23. (In Russ.).

Dervis E. Oral implications of osteoporosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100(3):349–56. https://doi.org/10.1016/j.tripleo.2005.04.010.

Zhu L., Zhou C., Chen S. et al. Osteoporosis and alveolar bone health in periodontitis niche: a predisposing factors-centered review. Cells. 2022;11(21):3380. https://doi.org/10.3390/cells11213380.

Khosla S., Oursler M.J., Monroe D.G. Estrogen and the skeleton. Trends Endocrinol Metab. 2012;23(11):576–81. https://doi.org/10.1016/j.tem.2012.03.008.

Prior J.C., Seifert-Klauss V.R., Giustini D. et al. Estrogen-progestin therapy causes a greater increase in spinal bone mineral density than estrogen therapy – a systematic review and meta-analysis of controlled trials with direct randomization. J Musculoskelet Neuronal Interact. 20171;17(3):146–54.

Prior J.C. Progesterone for the prevention and treatment of osteoporosis in women. Climacteric. 2018;21(4):366–74. https://doi.org/10.1080/13697137.2018.1467400.

Mills E.G., Yang L., Nielsen M.F. et al. The relationship between bone and reproductive hormones beyond estrogens and androgens. Endocr Rev. 2021;42(6):691–719. https://doi.org/10.1210/endrev/bnab015.

Sun L., Peng Y., Sharrow A.C. et al. FSH directly regulates bone mass. Cell. 2006;125(2):247–60. https://doi.org/10.1016/j.cell.2006.01.051.

Grey A.B. The skeletal effects of primary hyperparathyroidism. Baillieres Clin Endocrinol Metab. 1997;11(1):101–16. https://doi.org/10.1016/s0950-351x(97)80537-x.

Zaidi M., Moonga B.S., Huang C.L. Calcitonin and bone formation: a knockout full of surprises. J Clin Invest. 2002;110(12):1769–71. https://doi.org/10.1172/jci17425.

Giustina A., Mazziotti G., Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev. 2008;29(5):535–59. https://doi.org/10.1210/er.2007-0036.

Rosen C.J. Insulin-like growth factors and bone: the osteoporosis connection. Proc Soc Exp Biol Med. 1999;222(2):103–11. https://doi.org/10.3181/00379727-206-43726.

Zaidi M., Davies T.F., Zallone A. et al. Thyroid-stimulating hormone, thyroid hormones, and bone loss. Curr Osteoporos Rep. 2009;7(2):47–52. https://doi.org/10.1007/s11914-009-0009-0.

Arpaci D., Saglam F., Cuhaci F.N. et al. Serum testosterone does not affect bone mineral density in postmenopausal women. Arch Endocrinol Metab. 2015;59(4):292–6. https://doi.org/10.1590/2359-3997000000085.

Tao M.F., Sun D.M., Shao H.F. Low serum testosterone is associated with osteoporosis in postmenopausal women. Gynecol Endocrinol. 2022;38(5):409–13. https://doi.org/10.1080/09513590.2021.1930977.

Zhang H., Ma K., Li R.M. et al. Association between testosterone levels and bone mineral density in females aged 40-60 years from NHANES 2011-2016. Sci Rep. 202230;12(1):16426. https://doi.org/10.1038/s41598-022-21008-7.

Weinstein R.S. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am. 2012;41(3):595–611. https://doi.org/10.1016/j.ecl.2012.04.004.

Takeda S., Elefteriou F., Levasseur R. et al. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002;111(3):305–17. https://doi.org/10.1016/s0092-8674(02)01049-8.

Holick M.F. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–81. https://doi.org/10.1056/NEJMra070553.

Hoppé E., Bouvard B., Royer M. et al. Sex hormone-binding globulin in osteoporosis. Joint Bone Spine. 2010;77(4):306–12. https://doi.org/10.1016/j.jbspin.2010.03.011.

Weitzmann M.N. The role of inflammatory cytokines, the RANKL/OPG axis, and the immunoskeletal interface in physiological bone turnover and osteoporosis. Scientifica (Cairo). 2013;2013:125705. https://doi.org/10.1155/2013/125705.

Jeffcoat M.K. Osteoporosis: a possible modifying factor in oral bone loss. Ann Periodontol. 1998;3(1):312–21. https://doi.org/10.1902/annals.1998.3.1.312.

Dvorak G., Arnhart C., Heuberer S. et al. Peri-implantitis and late implant failures in postmenopausal women: a cross-sectional study. J Clin Periodontol. 2011;38(10):950–5. https://doi.org/10.1111/j.1600-051X.2011.01772.x.

Karoussis I.K., Müller S., Salvi G.E. et al. Association between periodontal and peri-implant conditions: a 10-year prospective study. Clin Oral Implants Res. 2004;15(1):1–7. https://doi.org/10.1111/j.1600-0501.2004.00982.x.

Black D.M., Rosen C.J. Postmenopausal osteoporosis. N Engl J Med. 2016;374(3):254–62. https://doi.org/10.1056/nejmc1602599.

Ruggiero S.L., Dodson T.B., Fantasia J. et al. Medication-related osteonecrosis of the jaw – 2014 update. J Oral Maxillofac Surg. 2014;72(10):1938–56. https://doi.org/10.1016/j.joms.2014.04.031.

Khan A.A., Morrison A., Hanley D.A. et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3–23. https://doi.org/10.1002/jbmr.2405.

Kuchler U., Luvizuto E.R., Tangl S. et al. Short-term teriparatide delivery and osseointegration: a clinical feasibility study. J Dent Res. 2011;90(8):1001–6. https://doi.org/10.1177/0022034511407920.

Bashutski J.D., Eber R.M., Kinney J.S. et al. Teriparatide and osseous regeneration in the oral cavity. N Engl J Med. 2010;363(25):2396–405. https://doi.org/10.1056/NEJMoa1005361.

Miller P.D., Hattersley G., Riis B.J. et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: the ACTIVE randomized clinical trial. JAMA. 2016;316(7):722–33. https://doi.org/10.1001/jama.2016.11136.

Tabatabai L., Cosman F., Curtis J.R. et al. Comparative effectiveness of abaloparatide and teriparatide in women 50 years of age and older: update of a real-world retrospective. Analysis. Endocr Pract. 2025;31(2):159–68. https://doi.org/10.1016/j.eprac.2024.10.017.

Cosman F., Crittenden D.B., Adachi J.D. et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532–43. https://doi.org/10.1056/NEJMoa1607948.

McClung M.R., Grauer A., Boonen S. et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412–20. https://doi.org/10.1056/NEJMoa1305224.

Giro G., Chambrone L., Goldstein A. et al. Impact of menopause hormone therapy on dental implant outcomes: a 5-year prospective study. Clin Implant Dent Relat Res. 2019;21(5):936–44. https://doi.org/10.1111/cid.12779.

Stanczyk F.Z., Archer D.F., Bhavnani B.R. Ethinyl estradiol and 17β-estradiol in contraceptives: pharmacokinetics, pharmacodynamics and risk assessment. Contraception. 2013;87(6):706–27. https://doi.org/10.1016/j.contraception.2012.12.011.

The authors declare that there are no conflicts of interest present.